Allergan enjoys ‘strong’ fourth quarter of 2009

Allergan has forecast improvements to its business performance in 2010 after experiencing a strong performance in the final quarter of 2009.

The healthcare firm has published its financial report for the three-month period ending December 31st 2009, during which its total product net sales rose to £1.2 billion (764,000 pounds).

This represents an increase of 15.9 per cent compared to the final quarter of 2008, an improvement which the firm credited to strong pharmaceuticals sales and the success of its commercial investment programme.

David Pyott, Allergan’s chairman of the board and chief executive officer, described the quarter as a strong one for the firm and predicted further upturns in the coming year.

He said: “In 2010 we look forward to rebuilding our cash-pay markets and to introducing some significant therapeutic innovations.”

Earlier this month, Allergan received approval from the Food and Drug Administration for its new dermal filler product Juvederm, based on supporting data from a clinical trial.